These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 27906698)

  • 1. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
    Ohta K; Nagase H; Suzukawa M; Ohta S
    Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics in the treatment of severe asthma.
    Quirce S; Phillips-Angles E; Domínguez-Ortega J; Barranco P
    Allergol Immunopathol (Madr); 2017 Dec; 45 Suppl 1():45-49. PubMed ID: 29108767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological therapies for eosinophilic asthma.
    Patel SS; Casale TB; Cardet JC
    Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics in allergic rhinitis.
    Bayar Muluk N; Cingi C
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(5 Suppl):43-52. PubMed ID: 37869947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
    Holgate ST; Djukanović R; Casale T; Bousquet J
    Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic treatment options for severe asthma.
    Hearn AP; Kent BD; Jackson DJ
    Curr Opin Immunol; 2020 Oct; 66():151-160. PubMed ID: 33212388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
    García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
    Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
    Dewilde S; Turk F; Tambour M; Sandström T
    Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
    D'Amato G; Bucchioni E; Oldani V; Canonica W
    Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
    Domingo C
    Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of mepolizumab for the treatment of severe asthma.
    Morjaria JB; Emma R; Fuochi V; Polosa R; Caruso M
    Expert Opin Biol Ther; 2019 Jun; 19(6):491-500. PubMed ID: 31009582
    [No Abstract]   [Full Text] [Related]  

  • 17. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements in biologic therapy in eosinophilic asthma.
    Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
    Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab in the treatment of severe eosinophilic asthma.
    Fainardi V; Pisi G; Chetta A
    Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.